Impact of meningococcal group B OMV vaccines, beyond their brief
Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity. Measures of efficacy indicate good protection against homologous strains in older...
Saved in:
Main Author: | Helen Petousis-Harris (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control
by: Paul Balmer, et al.
Published: (2018) -
Development of group B meningococcal vaccine: a progress review
by: Wei ZHAO, et al.
Published: (2022) -
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine
by: John L. Perez, et al.
Published: (2018) -
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
by: Emanuelle B. Gaspar, et al.
Published: (2021) -
Meningococcal serogroup B vaccines: Estimating breadth of coverage
by: Robert G. K. Donald, et al.
Published: (2017)